New Haven, CTNCT06414460Now EnrollingIRB Ready

Locally Advanced/Metastatic Solid Tumors Clinical Trial in New Haven, CT

Access cutting-edge locally advanced/metastatic solid tumors treatment through this clinical trial at a research site in New Haven. Study-provided care at no cost to qualified participants.

Sponsored by InSilico Medicine Hong Kong Limited

Quick Self-Assessment

See if you qualify for this New Haven location

Preparing your pre-screening questions…

Expert Care in New Haven

Access locally advanced/metastatic solid tumors specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related locally advanced/metastatic solid tumors treatment provided free

Apply for This New Haven Location

Check if you qualify for this locally advanced/metastatic solid tumors clinical trial in New Haven, CT

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New Haven

    Convenient for CT residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New Haven site if eligible
  4. 4Begin participation

About This Locally Advanced/Metastatic Solid Tumors Study in New Haven

The study has consists of two parts, a dose escalation part (Part 1) and a dose selection optimization part (Part 2). The primary objectives of this study are to evaluate the safety and tolerability of ISM3412 in participants with locally advanced/metastatic solid tumors, and to determine the RP2D of ISM3412.

Sponsor: InSilico Medicine Hong Kong Limited

Who Can Participate

Inclusion Criteria

Male or female participants with age ≥18 years at the time of signing the informed consent.
Histologically confirmed unresectable locally advanced or metastatic solid tumors with confirmed homozygous MTAP deletion, who have disease progression after standard therapy, intolerable to standard therapy, or for whom no standard therapy exists.
Have measurable or evaluable lesions in Part 1 and at least one measurable target lesion in Part 2 as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
ECOG PS (Eastern Cooperative Oncology Group Performance Status) ≤1.
Life expectancy of ≥12 weeks as judged by the investigator.
Adequate organ function as determined by medical assessment.
Capable of providing signed ICF and complying with the requirements and restrictions listed in the ICF and in this study protocol.

Exclusion Criteria

Prior treated with other MAT2A inhibitors and/or PRMT inhibitors.
Participation in other therapeutic clinical studies within 28 days or 5 half-lives (whichever is shorter) prior to first dose of study treatment.
Anti-tumor therapy (chemotherapy, immunotherapy, hormonal therapy, targeted therapy, biologic therapy, or other anti-tumor therapy, except for hormones for hypothyroidism or estrogen replacement therapy, anti-estrogen analogues, agonists required to suppress serum testosterone levels) within 28 days or 5 half-lives, whichever is shorter prior to first dose of study treatment.
Toxicities of prior therapy have not resolved to Grade ≤1 or to baseline (as evaluated by NCI CTCAE version 5.0)
History of another primary tumor that has been diagnosed or required therapy within the past 3 years.
Previous history of, or presence of Gilbert's syndrome.
Previous history of myelodysplastic syndrome.
Prior solid organ or hematopoietic stem cell transplant.
Known active central nervous system (CNS) primary tumor or untreated CNS metastases.
Have serious cardiovascular or cerebrovascular disease as per protocol.
Presence of uncontrolled systemic infection as per protocol.
Unwillingness or unable to comply with the requirements of oral drug administration, or presence of a gastro-intestinal condition. Other protocol inclusion and exclusion criteria may apply.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New Haven?

Yes, this clinical trial (NCT06414460) has an active research site in New Haven, CT that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Locally Advanced/Metastatic Solid Tumors Treatment Options in New Haven, CT

If you're searching for locally advanced/metastatic solid tumors treatment options in New Haven, CT, this clinical trial (NCT06414460) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New Haven research site is actively enrolling participants for this clinical trial. You'll receive care from experienced locally advanced/metastatic solid tumors specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all locally advanced/metastatic solid tumors clinical trials near you to find additional studies recruiting in your area.

More Leukemia Trials in New Haven, CT

See all leukemia clinical trials recruiting in New Haven — not just this study.

Browse Leukemia Trials in New Haven →

Browse More Trials by Condition

Leukemia TrialsAdvanced Solid Tumors TrialsAlzheimers Disease TrialsEssential Tremor TrialsAnkylosing Spondylitis TrialsAtopic Dermatitis TrialsErectile Dysfunction TrialsInterstitial Cystitis TrialsAll Conditions →

Ready to Join in New Haven?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New Haven, CT